Fate Therapeutics FATE

$2.00 -0.13 (-6.10%)

Valuation

Market cap: 261,210,000
Revenue TTM: $6,650,000
Net income TTM: $-136,320,000
PE ratio: 0.00
Forward PE: —
Profit margin: -2,049.92%
Debt to equity: 0.00

Trading

Volume: 813,317
Avg volume: 1,676,502
Day's range: $1.98 – $2.13
Shares out: 119,821,000
Stochastic %K: 18%
Beta: 2.52
Analysts: Sell
Price target: $5.74

Price

Company profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 858 875 1800
Website: https://www.fatetherapeutics.com
Address: 12278 Scripps Summit Drive, San Diego, United States

Latest news

No headlines yet.

Stocktwits

DoulosofChrist Oct 12, 11:10 AM

$FATE https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-appoints-jamie-harrell-senior-vice-president

1 replies

Nik7777 Oct 9, 2:33 PM

$FATE

0 replies

Rocketman808 Oct 8, 6:34 PM

$FATE drooling over 2.04 this am

0 replies

aquira Oct 8, 1:41 PM

$FATE looks like it's going back to 1.5-1.6 levels. Such a crappy company. What a waste of time and money. Lowest levels since June. Ugghhh

1 replies

Rocketman808 Oct 7, 7:29 PM

$FATE 200 day attack complete

1 replies

Randy2979 Oct 6, 11:56 PM

$FATE Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. In line with this decision, Caribou will implement workforce and cost reductions.

1 replies

Rocketman808 Oct 6, 9:38 PM

$FATE 2.27 or 2.59 doesnt really make a difference until out of that range. in “data loading mode”

0 replies

Merlintrader Oct 6, 5:11 PM

Latest company news, October 2: new employee inducement awards (options and RSUs). Next scheduled clinical program: ACR Convergence posters, November 8-9. Fate Therapeutics ($FATE): $15M CIRM Grant for RECLAIM-LN Explore the company, catalysts and risks in our research hub. https://www.merlintrader.com/fate-therapeutics-stock-hub/

0 replies